DK2753334T3 - Fap-aktiverede proteasomhæmmere til behandling af solide tumorer - Google Patents

Fap-aktiverede proteasomhæmmere til behandling af solide tumorer Download PDF

Info

Publication number
DK2753334T3
DK2753334T3 DK12827686.2T DK12827686T DK2753334T3 DK 2753334 T3 DK2753334 T3 DK 2753334T3 DK 12827686 T DK12827686 T DK 12827686T DK 2753334 T3 DK2753334 T3 DK 2753334T3
Authority
DK
Denmark
Prior art keywords
fap
treatment
solid tumors
proteasome inhibitors
activated proteasome
Prior art date
Application number
DK12827686.2T
Other languages
Danish (da)
English (en)
Inventor
Hung-Sen Lai
Sarah E Poplawski
William W Bachovchin
Original Assignee
Tufts College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts College filed Critical Tufts College
Application granted granted Critical
Publication of DK2753334T3 publication Critical patent/DK2753334T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
DK12827686.2T 2011-08-30 2012-08-30 Fap-aktiverede proteasomhæmmere til behandling af solide tumorer DK2753334T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161528824P 2011-08-30 2011-08-30
PCT/US2012/053140 WO2013033396A2 (en) 2011-08-30 2012-08-30 Fap-activated proteasome inhibitors for treating solid tumors

Publications (1)

Publication Number Publication Date
DK2753334T3 true DK2753334T3 (da) 2022-11-07

Family

ID=47757170

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12827686.2T DK2753334T3 (da) 2011-08-30 2012-08-30 Fap-aktiverede proteasomhæmmere til behandling af solide tumorer

Country Status (14)

Country Link
US (6) US9597410B2 (enExample)
EP (2) EP2753334B1 (enExample)
JP (2) JP6207509B2 (enExample)
CN (2) CN103945856A (enExample)
AU (2) AU2012301810B2 (enExample)
CA (1) CA2846852C (enExample)
DK (1) DK2753334T3 (enExample)
ES (1) ES2929179T3 (enExample)
HR (1) HRP20221320T1 (enExample)
HU (1) HUE060305T2 (enExample)
PL (1) PL2753334T3 (enExample)
PT (1) PT2753334T (enExample)
SI (1) SI2753334T1 (enExample)
WO (1) WO2013033396A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE060305T2 (hu) 2011-08-30 2023-02-28 Tufts College FAP-aktivált proteaszóma inhibitorok a szolid tumorok kezelésére
CA2893239A1 (en) * 2012-12-03 2014-06-12 F. Hoffmann-La Roche Ag Substituted triazole and imidazole compounds
EP3008212A4 (en) * 2013-06-10 2017-05-24 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
WO2015076359A1 (ja) * 2013-11-21 2015-05-28 国立大学法人北海道大学 プロテアソーム阻害性化合物
US9737556B2 (en) 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto
IL249370B (en) 2014-06-13 2022-06-01 Tufts College Fap-activated therapeutic agents, and uses related thereto
AU2015282627B2 (en) 2014-06-30 2020-04-02 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
ES2704056T3 (es) 2014-07-14 2019-03-14 Centrax Int Inc Compuestos de epoxicetona para la inhibición de enzimas
AU2015306574B2 (en) 2014-08-22 2020-07-23 Yafei Shanghai Biology Medicine Science & Technology Co. Ltd. Specifically activated micromolecular target coupling body in tumor microenvironment and use thereof
CN104231047B (zh) * 2014-08-22 2017-06-16 亚飞（上海）生物医药科技有限公司 水溶性靶向激活的紫杉醇衍生物及其制备和用途
US10675364B2 (en) * 2015-06-23 2020-06-09 The Board Of Trustees Of The Leland Stanford Junior University Rhodol fluorophores for near-infrared imaging
CN106588965A (zh) 2015-10-15 2017-04-26 北京大学 脲拟肽硼酸化合物及其药物组合物、制备方法和用途
CN105938123B (zh) * 2015-12-18 2018-09-14 重庆两江药物研发中心有限公司 一种卡非佐米中间体中杂质的检测方法
EP3426674A4 (en) 2016-03-09 2019-08-14 Blade Therapeutics, Inc. CYCLIC KETO AMID COMPOUNDS AS CALPAIN MODULATORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
MX392422B (es) 2016-06-21 2025-03-24 Orion Ophthalmology LLC Derivados de prolinamida heterociclica
US11292801B2 (en) 2016-07-05 2022-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
AU2017336523B2 (en) 2016-09-28 2022-07-21 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
WO2018111989A1 (en) 2016-12-14 2018-06-21 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy
ES2988845T3 (es) 2017-01-09 2024-11-21 Onkosxcel Therapeutics Llc Procedimientos predictivos y diagnósticos para cáncer de próstata
JP7022145B2 (ja) * 2017-04-04 2022-02-17 ジェネンテック， インコーポレイテッド 線維芽細胞活性化タンパク質（ｆａｐ）によって認識される基質とその使用方法
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
KR102005030B1 (ko) * 2017-10-31 2019-07-29 충북대학교 산학협력단 프로테아좀 억제제를 유효성분으로 포함하는 신경퇴행성 질환의 예방 또는 치료용 약학적 조성물
CN108191957B (zh) * 2017-12-30 2021-05-04 浙江大学 三肽大环衍生物及其制备方法和应用
JP2021512165A (ja) 2018-01-29 2021-05-13 コグノス・セラピューティクス・インコーポレイテッド ボルテゾミブの腫瘍内送達
CA3088326A1 (en) * 2018-02-06 2019-08-15 Universitat Heidelberg Fap inhibitor
CN112513052B (zh) * 2018-08-02 2022-12-16 正大天晴药业集团股份有限公司 氮杂环丁烷衍生物的硼酸酯
EP3833374B1 (en) 2018-08-06 2024-12-25 University Of Kentucky Research Foundation Proteasome inhibitors
GB201820320D0 (en) * 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for FAPalpha
EP4041747A4 (en) * 2019-10-11 2023-10-18 Mayo Foundation for Medical Education and Research PROTEASOME HIBITORS
CN111235221B (zh) * 2020-01-22 2022-08-05 北京大学第一医院 一种fap抑制剂的活性检测方法
CZ309380B6 (cs) * 2020-03-30 2022-10-26 Ústav organické chemie a biochemie AV ČR v. v. i Sloučeniny pro inhibici fibroblastového aktivačního proteinu
AU2021293261A1 (en) 2020-06-17 2023-02-02 University Of Utah Research Foundation Biomarker based patient selection for proteasome inhibitor treatment
EP4263535A1 (en) 2020-12-17 2023-10-25 Astrazeneca AB N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides
JP2023554396A (ja) * 2020-12-17 2023-12-27 トラスティーズ オブ タフツ カレッジ Ｆａｐ活性化ラジオセラノスティクスおよび関連する使用
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
WO2024140736A1 (zh) * 2022-12-27 2024-07-04 上海美悦生物科技发展有限公司 三肽环氧酮化合物、药物组合物及其制备方法和用途
WO2025159301A1 (ko) * 2024-01-24 2025-07-31 서울대학교산학협력단 섬유아세포 활성화 단백질에 의해 활성화되는 프로드러그 화합물

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
CA1341029C (en) 1985-02-04 2000-06-20 Michael Kolb Peptidase inhibitors
US4935493A (en) 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
US5462928A (en) 1990-04-14 1995-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type IV
US6825169B1 (en) 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
WO1995025223A1 (en) 1994-03-11 1995-09-21 Wilson Greatbatch Ltd. Low power electromagnetic pump
US5580979A (en) 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6180402B1 (en) 1996-11-20 2001-01-30 Qlt Inc. Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor
IL135068A (en) 1997-09-29 2004-03-28 Point Therapeutics Inc Stimulation of hematopoietic cells in vitro
US6803357B1 (en) 1998-02-02 2004-10-12 New England Medical Center Hospitals, Inc. Method of regulating glucose metabolism, and reagents related thereto
KR20010052302A (ko) 1998-05-04 2001-06-25 바바라 피. 월너 조혈 자극
WO1999062914A1 (en) 1998-06-05 1999-12-09 Point Therapeutics, Inc. Cyclic boroproline compounds
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
US6285178B1 (en) 1999-02-11 2001-09-04 Battelle Memorial Institute Power supply
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
JP2005511636A (ja) 2001-11-26 2005-04-28 トラスティーズ オブ タフツ カレッジ 自己免疫疾患の治療方法及びそれに関する試薬
WO2003045977A2 (en) 2001-11-26 2003-06-05 Trustees Of Tufts College Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes
EP2204181A3 (en) 2002-04-30 2010-09-22 Trustees Of Tufts College Protease inhibitors
JP2006506442A (ja) 2002-07-09 2006-02-23 ポイント セラピューティクス， インコーポレイテッド ボロプロリン化合物併用療法
JP4699374B2 (ja) 2003-05-15 2011-06-08 トラスティーズ オブ タフツ カレッジ 安定なペプチド及びポリペプチドアナログ治療剤
KR101292707B1 (ko) 2004-02-23 2013-08-02 트러스티즈 오브 터프츠 칼리지 디펩티딜펩티다아제 ⅳ의 억제제
US20060063719A1 (en) 2004-09-21 2006-03-23 Point Therapeutics, Inc. Methods for treating diabetes
CA2606785A1 (en) * 2005-05-19 2006-11-23 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
KR20080030079A (ko) * 2005-07-05 2008-04-03 트러스티즈 오브 터프츠 칼리지 섬유아세포 활성 단백질 알파의 억제제
AU2006201635A1 (en) * 2005-10-20 2007-05-10 Ludwig Institute For Cancer Research Novel inhibitors and methods for their preparation
CA2633803A1 (en) * 2005-12-19 2007-09-07 Trustees Of Tufts College Soft protease inhibitors and pro-soft forms thereof
MX2009000132A (es) * 2006-06-30 2009-01-26 Schering Corp Metodo para el uso de piperidinas sustituidas que incrementan la actividad de p53.
JP2010523477A (ja) * 2007-03-20 2010-07-15 トラスティーズ オブ タフツ カレッジ 線維芽細胞活性化タンパク質の阻害剤、およびそれを使用する方法
US20100184706A1 (en) * 2007-03-20 2010-07-22 Bachovchin William W Fap-activated chemotherapeutic compounds, and methods of use thereof
WO2009006473A2 (en) * 2007-07-05 2009-01-08 Trustees Of Tufts College Pro-soft polypeptide proteasome inhibitors, and methods of use thereof
GEP20125599B (en) * 2007-08-06 2012-08-10 Millennium Pharm Inc Proteasome inhibitors
CA2696579C (en) * 2007-08-17 2017-01-24 Boehringer Ingelheim International Gmbh Purine derivatives for use in the treatment of fab-related diseases
US8969027B2 (en) 2008-03-03 2015-03-03 Kansas State University Research Foundation Protease assay
JP5801585B2 (ja) 2011-03-30 2015-10-28 株式会社ケーヒン 燃料噴射制御システム
HUE060305T2 (hu) 2011-08-30 2023-02-28 Tufts College FAP-aktivált proteaszóma inhibitorok a szolid tumorok kezelésére

Also Published As

Publication number Publication date
AU2012301810A1 (en) 2014-04-10
EP4144354A1 (en) 2023-03-08
US20210379190A1 (en) 2021-12-09
CA2846852A1 (en) 2013-03-07
US20250367304A1 (en) 2025-12-04
ES2929179T3 (es) 2022-11-25
US12214047B2 (en) 2025-02-04
HUE060305T2 (hu) 2023-02-28
US10517955B2 (en) 2019-12-31
US20140255300A1 (en) 2014-09-11
CN108383893A (zh) 2018-08-10
CN103945856A (zh) 2014-07-23
US20200323994A1 (en) 2020-10-15
AU2017204121A1 (en) 2017-07-06
US9956297B2 (en) 2018-05-01
WO2013033396A3 (en) 2014-05-08
CA2846852C (en) 2021-01-12
AU2012301810B2 (en) 2017-06-01
SI2753334T1 (sl) 2023-01-31
US9597410B2 (en) 2017-03-21
EP2753334A4 (en) 2015-07-01
US20160346401A1 (en) 2016-12-01
HRP20221320T1 (hr) 2023-01-06
JP2014527070A (ja) 2014-10-09
EP2753334B1 (en) 2022-10-19
JP2018016629A (ja) 2018-02-01
JP6207509B2 (ja) 2017-10-04
US11065339B2 (en) 2021-07-20
EP2753334A2 (en) 2014-07-16
WO2013033396A2 (en) 2013-03-07
EP4144354B1 (en) 2025-11-26
PT2753334T (pt) 2022-11-03
US20190054181A1 (en) 2019-02-21
PL2753334T3 (pl) 2022-12-12

Similar Documents

Publication Publication Date Title
DK2753334T3 (da) Fap-aktiverede proteasomhæmmere til behandling af solide tumorer
DK3400944T3 (da) Ibat-inhibitorer til behandling af leversygdomme
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
SMT201700109B (it) Inibitori di istone demetilasi
HUE057264T2 (hu) Eljárás új IDH1 inhibitorok elõállítására
DK3628670T3 (da) Saltform til ezh2-hæmning
DK2558105T3 (da) Bardoxolonmethyl til behandling af fedme
PT2523661T (pt) Inibidores de nkcc para o tratamento de autismo
HUE040455T2 (hu) T-sejt aktiválás inhibitorai
EP2734529A4 (en) BTK INHIBITORS
HRP20180237T1 (hr) Metode za liječenje hcv-a
CO6930358A2 (es) Compuestos inhibidores de metaloenzimas
HRP20180809T1 (hr) Inhibicijski spojevi metaloenzima
EP2782570A4 (en) HETEROCYCLIC INHIBITORS OF GLUTAMINASE
DK3412687T3 (da) Fremgangsmåder til behandling af dlbcl
DK2785801T4 (da) Fremgangsmåde til formindskelse af isdannelse på et underlag
DK2635282T3 (da) Sammensætninger til behandling af myelofibrose
DK3246042T3 (da) Lægemiddelresistent immunterapi til behandling af cancer
DK2662094T3 (da) Fremgangsmåder til cylodextrinkompleksdannelse til formulering af peptidproteasomhæmmere
DK2500036T3 (da) MET-hæmmere til øgning af virkningen af radioterapi
EP2858975A4 (en) FBXO3 INHIBITORS
EP2629616A4 (en) SUBSTITUTED AMINO-TRIAZOLYL-PDE10-HEMMER
DK2701707T3 (da) Fremgangsmåde til behandling af dyskinesi
DK3536410T3 (da) Fremgangsmåde til behandling af affaldsgenstande